# Blueberry Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/blueberry-therapeutics

- Industry: Biotechnology
- Headquarters: Macclesfield, UK
- Website: www.blueberrytherapeutics.com
- Total disclosed funding: $20M
- Latest round: Series B (Jan 14, 2021)
- Investors on record: 6

## About

Based in Cheshire, UK, and founded in 2011, Blueberry Therapeutics Ltd develops nanopolymer drugs for patients with skin and nail infections. The company was founded by Michael Davies. In 2021, Blueberry Therapeutics Ltd raised funding from Medical Incubator Japan and Connecticut Skin Institute.

The company works with pharmaceutical companies, by offering nanomedicines. Blueberry Therapeutics Ltd provides therapies using nanopolymer drug system for skin and nail diseases such as Onychomycosis (Fungal Nail), Tinea pedis (athlete’s foot), acne, and Atopic Dermatitis (Eczema).

The company generates revenue by selling nanomedicine for skin and nail diseases to pharmaceutical companies. In 2019, Blueberry Therapeutics Ltd reported revenue of GBP 0.47 million.

Following its funding in 2021, the company plans to use the investment towards product development.

## Funding rounds

- Series B, Jan 14, 2021, $4.9M — Medical Incubator Japan, Connecticut Skin Institute, M.D.
- Series B, Aug 14, 2018, $13M — AllianceBernstein, CMS Ventures, A&B (HK)
- Seed, Sep 8, 2014, $1.9M — Incline Equity Partners

## Investors

- Incline Equity Partners (https://capitalatlas.ai/funds/incline-equity-partners) — Seed
- AllianceBernstein (https://capitalatlas.ai/funds/alliancebernstein) — Series B
- CMS Ventures (https://capitalatlas.ai/funds/cms-ventures) — Series B
- A&B (HK) — Series B
- Medical Incubator Japan (https://capitalatlas.ai/funds/medical-incubator-japan) — Series B
- Connecticut Skin Institute, M.D. — Series B